- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04517149
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This Phase 1/2 study will gather data in an observational phase Natural History Cohort to further characterize and evaluate natural disease progression in male patients with genetically-confirmed X-linked retinitis pigmentosa (XLRP) caused by mutations in the gene encoding retinitis pigmentosa GTPase regulator (RPGR). The study will also evaluate the safety and tolerability, as assessed by frequency and severity of ocular and systemic adverse events, as well as preliminary clinical efficacy of a single intravitreal (IVT) injection of 4D-125 at two dose levels in this patient population in one or both eyes (the contralateral eye dose provided the subject is eligible and provides consent).
4D-125 has been developed as a gene replacement therapy for XLRP. After receiving 4D-125, patients will be followed for 24 months with continued safety follow-up and 36 additional months of long-term follow-up. Secondary endpoints will assess preliminary efficacy measures over time after 4D-125 administration.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Gainesville, Florida, United States, 32607
- Vitreo Retinal Associates
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- University of Michigan Kellogg Eye Center
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center/Edward Harkness Eye Institute
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Eye Center/Dept. of Ophthalmology
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Casey Eye Institute, Oregon Health and Science University
-
-
Texas
-
Dallas, Texas, United States, 75231
- Retina Foundation of the Southwest
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Natural History Key Inclusion Criteria:
- Male, ≥ 6 years of age at the time of informed consent
- Hemizygous non-syndromic RPGR mutation confirmed by genetic testing
Interventional Key Inclusion Criteria:
- Male, ≥12 years of age
- Hemizygous non-syndromic RPGR mutation confirmed by genetic testing
- Phase 1 Dose Exploration: At least one eye amenable to IVT injection and BCVA ≤ 78 ETDRS letters (~20/32) and ≥ 34 ETDRS letters (~20/200)
- Phase 2 Dose Expansion: At least one eye amenable to IVT injection AND both eyes must have BCVA ≥ 34 ETDRS letters (~20/200)
Key Exclusion Criteria (all cohorts)
- Patient has previously received any AAV treatment
- Pre-existing eye conditions or surgical complications that would preclude participation in an interventional clinical trial or interfere with the interpretation of study endpoints
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 4D-125 Dose Exploration
Dose 1 and Dose 2 4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1. The contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent. |
4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
|
Experimental: 4D-125 Dose Expansion
4D-125 will be administered at the assigned dose level as a single dose, IVT injection on Day 1 in both adults and pediatric participants.
For adult participants only, the contralateral eye may also be dosed with 4D-125 as a single dose, IVT injection provided the subject is eligible and provides consent.
|
4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
|
Other: Observational
Natural History
|
Natural History
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parameters
Time Frame: 24 months to 60 Months
|
24 months to 60 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Schonmei Lee, MD, 4D Molecular Therapeutics
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4D-125-C001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on X-Linked Retinitis Pigmentosa
-
NightstaRx Ltd, a Biogen CompanyEnrolling by invitationChoroideremia | X-Linked Retinitis PigmentosaUnited States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
-
MeiraGTx UK II LtdSyne Qua Non Limited; Bionical EmasCompletedGene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)X-Linked Retinitis PigmentosaUnited Kingdom, United States
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaBelgium, Canada, United States, Israel, United Kingdom, Spain, Denmark, France, Italy, Netherlands, Switzerland
-
Janssen Research & Development, LLCJanssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, Canada, Israel, United Kingdom, Spain, Denmark, France, Belgium, Italy, Netherlands, Switzerland
-
BiogenCompletedX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
Applied Genetic Technologies CorpCompletedX-Linked Retinitis PigmentosaUnited States
-
Janssen Research & Development, LLCActive, not recruitingX-Linked Retinitis PigmentosaUnited States, United Kingdom
-
Beacon TherapeuticsRecruitingX-Linked Retinitis PigmentosaUnited States
-
Janssen Pharmaceutical K.K.RecruitingX-Linked Retinitis PigmentosaJapan
-
Frontera TherapeuticsPeking Union Medical College Hospital; Eye & ENT Hospital of Fudan University; Henan Provincial People's HospitalRecruitingX-Linked Retinitis PigmentosaChina
Clinical Trials on 4D-125 IVT Injection
-
4D Molecular TherapeuticsRecruitingNeovascular (Wet) Age-Related Macular DegenerationUnited States, Puerto Rico
-
4D Molecular TherapeuticsRecruitingDiabetic Retinopathy | Diabetic Macular EdemaUnited States, Puerto Rico
-
Alvotech Swiss AGActive, not recruitingChorioretinal Vascular DiseaseGeorgia
-
Astellas Pharma Europe B.V.CompletedDiabetes Mellitus | Diabetic Macular EdemaUnited States
-
University of Wisconsin, MadisonCompleted
-
University of Sao PauloCompletedDiabetic Macular Edema
-
The Methodist Hospital Research InstituteActive, not recruiting
-
Jagiellonian UniversityCompletedPain, Postoperative | Knee Osteoarthritis | Arthroplasty Complications | Perioperative ComplicationPoland
-
M.D. Anderson Cancer CenterCompletedRecurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid LiposarcomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States